Opioid Withdrawal Symptoms in Critically Ill Patients

Sponsor
Mahidol University (Other)
Overall Status
Completed
CT.gov ID
NCT03374722
Collaborator
(none)
55
1
9.2
6

Study Details

Study Description

Brief Summary

Most critically ill patients encounter pain and distress from acute illness, medical procedures and devices as well as routine care in the intensive care units (ICU). Opioids are principal analgesics that alleviate moderate to severe pain and facilitate patients to co-operate the course of treatment. However, prolong administration of opioids especially in mechanically ventilated patients can cause withdrawal symptoms if analgesics are rapidly weaning or acutely disruption. The opioid withdrawal symptoms (OWS) are well reported in critically ill children that cause discomfort and prolong weaning from mechanical ventilation. Weaning opioids and treatment of withdrawal symptoms are needed in order to decrease ventilator days, ICU and hospital length of stay. Conversely, there is lack of knowledge about incidence, clinical presentation, time course and appropriated assessment tool for withdrawal detection. Therefore, we conduct the study to explore an incidence of OWS, to identify factors associated OWS, to establish the assessment tool for OWS, and to report efficacy of the pharmacological treatment for OWS, in adult critically ill patients.

Condition or Disease Intervention/Treatment Phase

Detailed Description

The primary objective of the study is to explore incidence of OWS in adult critically ill patients. The secondary objectives are 1) to identify factor associated OWS, 2) establish the assessment tool for OWS for adults and 3) to report efficacy of the pharmacological treatment in OWS in adults patients.

Study Design

Study Type:
Observational
Actual Enrollment :
55 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Opioid Withdrawal Symptoms in Critically Ill Patients
Actual Study Start Date :
Jan 1, 2018
Actual Primary Completion Date :
Aug 31, 2018
Actual Study Completion Date :
Oct 7, 2018

Arms and Interventions

Arm Intervention/Treatment
Mechanically ventilated critically ill patients

Mechanically ventilated critically ill patients who receive opioid as continuous infusion for more than 24 hours

Drug: Opioids
Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased

Outcome Measures

Primary Outcome Measures

  1. Incidence of opioid withdrawal symptoms [0, 1, 3, 6, 24 and 72 hour after reduction or discontinuation of intravenous opioid]

    Incidence of opioid withdrawal symptoms detected by self-developed assessment tool or the Diagnostic and Statistical Manual 5th edition (DSM-V)

Secondary Outcome Measures

  1. Weaning days [28 days]

    Time from initial weaning from mechanical ventilator until extubation

  2. Ventilator days [28 days]

    Time from intubation until extubation

  3. ICU length of stay [28 days]

    Time from admission to ICU until discharge from ICU

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥18 years

  • On mechanical ventilator at least 24 hours

  • Received continuous infusion of opioid at least 24 hours

  • Patient or legal surrogate who is willing and able to provide written informed consent and comply with all protocol requirements

Exclusion Criteria:
  • Severely disturbed behavior pattern on account of underlying neurological disease (status epilepticus, encephalopathy, head trauma, brain injury, spinal cord injury)

  • Preexisting psychiatric diagnosis

  • Substance abuse prior to ICU admission

  • Chronic alcohol drinking

  • Pregnancy

  • End-of-life care

  • Death during ICU admission or during opioid IV infusion

Contacts and Locations

Locations

Site City State Country Postal Code
1 Faculty of Pharmacy, Mahidol University Ratchathewi Bangkok Thailand 10400

Sponsors and Collaborators

  • Mahidol University

Investigators

  • Principal Investigator: Suthinee Taesotikul, Pharm.D., Faculty of Pharmacy, Mahidol university

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Suthinee Taesotikul, Principal investigator, Mahidol University
ClinicalTrials.gov Identifier:
NCT03374722
Other Study ID Numbers:
  • 10-60-68
First Posted:
Dec 15, 2017
Last Update Posted:
Oct 9, 2018
Last Verified:
Oct 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 9, 2018